|Bid||0.00 x 28400|
|Ask||0.00 x 2100|
|Day's range||104.70 - 106.50|
|52-week range||97.12 - 123.90|
|PE ratio (TTM)||12.08|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Bayer and Monsanto (NYSE: MON) today announced that the Committee on Foreign Investment in the United States (“CFIUS”) has completed its review of the proposed merger, and has concluded that there are no unresolved national security concerns with respect to the transaction. The acquisition is subject to customary closing conditions, including receipt of required regulatory approvals. Bayer and Monsanto will continue to cooperate with the authorities in order to complete the transaction in early 2018.
READING, U.K.--(BUSINESSWIRE)-- Bayer’s data shows Xarelto ® ▼ (rivaroxaban) significantly lowers the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or ...
CARY, N.C.--(BUSINESSWIRE)-- Following its Oct. 5, 2016 acquisition of Bayer Garden and Bayer Advanced consumer businesses, SBM has entered into an agreement to acquire Bayer’s Pasadena, Texas production ...